Publication Date:
2020
abstract:
Pharmacological interference on L-thyroxine (L-T4) therapy can be exerted at several
levels, namely from the hypothalamus/pituitary through the intestine, where the absorption
of exogenous L-T4 takes place. A number of medications interfere with L-T4 therapy,
some of them also being the cause of hypothyroidism. The clinician should be aware that
some medications simply affect thyroid function tests with no need of modifying the dose
of L-T4 that the patient was taking prior to their prescription. Usually, the topic of
pharmacological interference on L-T4 therapy addresses the patient with primary
hypothyroidism, in whom periodic measurement of serum thyrotropin (TSH) is the
biochemical target. However, this minireview also addresses the patient with central
hypothyroidism, in whom the biochemical target is serum free thyroxine (FT4). This
minireview also addresses two additional topics. One is the costs associated with
frequent monitoring of the biochemical target when L-T4 is taken simultaneously with
the interfering drug. The second topic is the issue of metabolic/cardiovascular
complications associated with undertreated hypothyroidism.
Iris type:
14.a.1 Articolo su rivista
Keywords:
levothyroxine, hypothyroidism, pharmacological interferents, metabolic complications,
cardiovascular complications
List of contributors:
Benvenga, S
Published in: